China-based biopharmaceutical firm IMPACT Therapeutics has completed its Series D+ funding round at 400 million yuan ($55.2 million) to advance its pipeline of anti-cancer therapeutics.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
